Drug Profile
CIGB 210
Alternative Names: CIGB-210Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Class Antiretrovirals
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for HIV infections in Cuba (unspecified route), prior to August 2023 (Center for Genetic Engineering and Biotechnology pipeline, August 2023)
- 28 Jan 2019 No recent reports of development identified for preclinical development in HIV-infections in Cuba
- 31 Dec 2014 Preclinical trials in HIV infections in Cuba (unspecified route) prior to December 2014